Patent application number | Description | Published |
20080306066 | NON-IMIDAZOLE HETEROCYCLIC COMPOUNDS - Certain non-imidazole heterocyclic compounds are histamine H | 12-11-2008 |
20080306085 | NON-IMIDAZOLE ARYLOXYALKYLAMINES - Substituted aryloxyalkylamines of formula (I), compositions containing them, and methods of making and using them to treat histamine-mediated conditions. | 12-11-2008 |
20080317671 | NON-IMIDAZOLE HETEROCYCLIC COMPOUNDS - Certain non-imidazole heterocyclic compounds are histamine H | 12-25-2008 |
20090263322 | OCTAHYDRO-INDOLIZINE AND QUINOLIZINE AND HEXAHYDRO-PYRROLIZINES - The invention features substituted fused bicyclic compounds, pharmaceutical compositions containing them, and methods of using them to treat or prevent histamine-mediated diseases and conditions. | 10-22-2009 |
20090291903 | SUBSTITUTED PYRROLIDINE AMIDES AS MODULATORS OF THE HISTAMINE H3 RECEPTOR - Certain substituted pyrrolidine amide compounds are histamine H | 11-26-2009 |
20100004241 | NON-IMIDAZOLE ARYLOXYALKYLAMINES - Substituted aryloxyalkylamines of formula (I), compositions containing them, and methods of making and using them to treat histamine-mediated conditions. | 01-07-2010 |
20100022539 | Isoxazole Compounds as Histamine H3 modulators - Certain isoxazole compounds are histamine H | 01-28-2010 |
20120015957 | PIPERAZINYL DERIVATIVES USEFUL AS MODULATORS OF THE NEUROPEPTIDE Y2 RECEPTOR - The present invention is directed to piperidinyl and piperazinyl derivatives of formula (I) useful as inhibitors of the NPY Y2 receptor, pharmaceutical compositions comprising said compounds, processes for the preparation of said compounds and the use of said compounds for the treatment and/or prevention of disorders, diseases and conditions mediated by the NPY Y2 receptor. | 01-19-2012 |
20120129870 | PIPERAZINYL DERIVATIVES USEFUL AS MODULATORS OF THE NEUROPEPTIDE Y2 RECEPTOR - The present invention is directed to piperidinyl and piperazinyl derivatives of formula (II) useful as inhibitors of the NPY Y2 receptor, pharmaceutical compositions comprising said compounds, processes for the preparation of said compounds and the use of said compounds for the treatment and/or prevention of disorders, diseases and conditions mediated by the NPY Y2 receptor. | 05-24-2012 |
20120202783 | FUSED HETEROCYCLIC COMPOUNDS AS OREXIN RECEPTOR MODULATORS - Disubstituted 3,8-diaza-bicyclo[4.2.0]octane and 3,6-diazabicyclo[3.2.0]heptane compounds are described, which are useful as orexin receptor modulators. Such compounds may be useful in pharmaceutical compositions and methods for the treatment of diseased states, disorders, and conditions mediated by orexin activity, such as insomnia. | 08-09-2012 |
20120208812 | DISUBSTITUTED OCTAHYDROPYRROLO[3,4-c]PYRROLES AS OREXIN RECEPTOR MODULATORS - Disubstituted octahydropyrrolo[3,4-c]pyrrole compounds are described, which are useful as orexin receptor modulators. Such compounds may be useful in pharmaceutical compositions and methods for the treatment of diseased states, disorders, and conditions mediated by orexin activity, such as insomnia. | 08-16-2012 |
20130137672 | DISUBSTITUTED OCTAHYDROPYRROLO[3,4-c]PYRROLES AS OREXIN RECEPTOR MODULATORS - Certain disubstituted 3,8-diaza-bicyclo[4.2.0]octane and 3,6-diazabicyclo[3.2.0]heptane are described, which are useful as orexin inhibitors. Such compounds may be useful in pharmaceutical compositions and methods for the treatment of diseased states, disorders, and conditions mediated by orexin activity, such as insomnia. | 05-30-2013 |
20140038943 | SEROTONIN RECEPTOR MODULATOR - Certain biphenyic compounds are serotonin modulators useful in the treatment of serotonin-mediated diseases. | 02-06-2014 |
20140179697 | DISUBSTITUTED OCTAHYDROPYRROLO[3,4-c]PYRROLES AS OREXIN RECEPTOR MODULATORS - Disubstituted octahydropyrrolo[3,4-c]pyrrole compounds are described, which are useful as orexin receptor modulators. Such compounds may be useful in pharmaceutical compositions and methods for the treatment of diseased states, disorders, and conditions mediated by orexin activity, such as insomnia. | 06-26-2014 |